재발성 비소세포폐암에서 Pemetrexed 치료 효과와 Thymidylate Synthase 발현의 관계 = Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression

다국어 초록 (Multilingual Abstract)

Background: Pemetrexed, a multi-targeted antifolate has been used as a second line treatment against non-small cell lung cancer (NSCLC). We aimed to clarify the efficacy and survival according to line of treatment, histologic type, and expression of thymidylate synthase (TS). Methods: Ninety-eight patients were treated with pemetrexed as a second line treatment (n=43) or as an additional course of treatment (n=55). TS expression was studied with immunohistochemistry and graded as 0 to 3 based on the extent of expression. Results: The response rate (RR) in 98 subjects was 10.2% and the disease control rate (DCR=PR＋SD) was 30.6%. RR and DCR were 12.7% and 32.7% in non-squamous cell carcinoma (NSQC) compared to 7.0% and 27.9% in squamous cell carcinoma (SQC) (p＞.05). No significant differences in RR and DCR were observed between a second line group (4.7%, 20.9%) and a further line group (14.5%, 38.2%). A similar trend was observed in the 88 response evaluable subjects. TS was expressed in 28.6% (grade 1), 24.5% (grade 2) and 7.1% (grade 3), respectively, and it was not expressed in 39.8% of subjects. TS expression rate was significantly higher in the SQC (72.1%) compared to NSQC (50.9%, p=0.033). However, the efficacy of pemetrexed was not significantly different by the extent of TS expression. Conclusion: Pemetrexed showed efficacy, not only in a second-line setting, but also in further lines of treatment for NSCLC. The efficacy of pemetrexed tended to be higher in patients with NSQC compared to SQC. TS expression rate was significantly higher in SQC compared to NSQC.

참고문헌 (Reference)

1 Breathnach OS, "Twenty-two years of phase III trials for patients with advanced non-smallcell lung cancer: sobering results" 19 : 1734-1742, 2001

2 Rustum YM, "Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors" 15 : 389-400, 1997

3 Johnston PG, "Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors" 55 : 1407-1412, 1995

4 Johnston PG, "The role of thymidylate synthase expression in prognosis and outcome of ad juvant chemotherapy in patients with rectal cancer" 12 : 2640-2647, 1994

5 Ceppi P, "Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase" 107 : 1589-1596, 2006

6 Hanna N, "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy" 22 : 1589-1597, 2004

7 Shepherd FA, "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy" 18 : 2095-2103, 2000

8 Vogelzang NJ, "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma" 21 : 2636-2644, 2003

9 Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advancedstage non-small-cell lung cancer" 26 : 3543-3551, 2008

10 Rossi A, "Pemetrexed in the treatment of advanced non-squamous lung cancer" 2009

11 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 : 205-216, 2000

12 In KH, "Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study" 64 : 232-237, 2009

13 Hanauske AR, "In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression" 25 : 417-423, 2007

14 Nakagawa T, "Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC)" 43 : 145-149, 2004

15 Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer" 353 : 123-132, 2005

16 Sun JM, "Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer" 39 : 27-32, 2009

17 Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer" 346 : 92-98, 2002

18 Korean Association for the Study of Lung Cancer, "Clinical practice guidelines in oncology. Non-small cell lung cancer"

19 de Marinis F, "Clinical evidence for secondand third-line treatment options in advanced non-small cell lung cancer" 13 (13): 14-20, 2008

20 Murillo JR, "Chemotherapy given near the end of life by community oncologists for advanced nonsmall cell lung cancer" 11 : 1095-1099, 2006

21 Haqqani AS, "Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens" 47 : 1563-1574, 1999

22 Rodriguez-Bigas MA, "Biochemical modulation of fluoropyrimidines and other drugs. in Colorectal cancer" Mosby 509-522, 1993

23 Pfister DG, "American Society of Clinical Oncology treatment of unresectable non- small cell lung cancer guideline: update 2003" 22 : 330-353, 2004

24 Massarelli E, "A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer" 39 : 55-61, 2003